State Medicaid DUR Board Meeting
General Information
- Government Type
- State Agency
- Entity
- Department of Health and Human Services (DHHS)
- Public Body
- Drug Utilization Review Board
Notice Information
- Notice Title
- State Medicaid DUR Board Meeting
- Notice Type(s)
- Meeting
- Event Start Date & Time
- September 11, 2025 07:15 AM
- Event End Date & Time
- September 11, 2025 08:30 AM
- Event Deadline Date & Time
- 09/11/25 08:30 AM
- Description/Agenda
- Drug Utilization Review Board Meeting Agenda Thursday, September 11, 2025 7:15 a.m. to 8:30 a.m. Google Meet joining info Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306# Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints. 1) Call to order - Sharon Weinstein, MD a) Welcome and Introductions b) Housekeeping - Luis Moreno, PharmD c) Review and Approval of Minutes 2) Prior Authorization Updates - Luis Moreno, PharmD a) Kebilidi (eladocagene exuparvovec-tneq) b) Yeztugo (lenacapavir) c) Skysona (elivaldogene autotemcel) 3) Public Comment 4) Review Prior Authorization Criteria a) Monoclonal Antibodies for Atopic Dermatitis- Kyu Yun Park, PharmD i) Committee Discussion/Questions ii) Committee Action b) Prophylaxis HAE - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action c) Adzynma (ADAMTS13, recombinant-krhn) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action b) Cablivi (caplacizumab-yhdp) - Skylar Fenton, PharmD i) Committee Discussion/Questions ii) Committee Action c) Piqray (alpelisib) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action d) Nuedexta (dextromethorphan/quinidine) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action 5) Next meeting scheduled a) Date: October 9, 2025 b) Topic: Concomitant use of oral buprenorphine-containing products with full-agonist opioids, and the use of oral buprenorphine-containing products (other than Belbucca) for pain. 6) Adjourned - Sharon Weinstein, MD
- Notice of Special Accommodations (ADA)
- In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
- Notice of Electronic or Telephone Participation
- Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Meeting Information
- Meeting Location
-
Video/Teleconferencing
Video/Teleconferencing, UT 84116
Show in Apple Maps Show in Google Maps - Contact Name
- Luis Moreno
- Contact Email
- lmoreno@utah.gov
- Contact Phone
- 801-538-6155
Notice Posting Details
- Notice Posted On
- August 28, 2025 04:47 PM
- Notice Last Edited On
- August 28, 2025 05:01 PM
- Deadline Date
- September 11, 2025 08:30 AM
Notice Revision History
| Revision Number | Notice Edited On | Edited By |
|---|---|---|
| 2 | August 28, 2025 05:01 PM | cdevashrayee@utah.gov |
| 1 | August 28, 2025 04:50 PM | cdevashrayee@utah.gov |
Subscribe
Subscribe by Email
Subscription options will send you alerts regarding future notices posted by this Body.